Rheumatology Medical News about Bone mass, PSQ, Alendronate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass
Osteoporosis International, 08/12/09

Kendler DL et al. – Data demonstrate that women with low bone mass preferred, were more satisfied, and less bothered with a 6-month injection regimen rather than a weekly alendronate tablet for treatment of osteoporosis.

Methods

Preference and Satisfaction Questionnaire (PSQ) was used to compare patient preference and satisfaction between a 6-mo sc injection and a weekly oral tablet for treatment of bone loss
Postmenopausal women with low bone mass were randomized to receive:
- A 6-mo sc denosumab injection (60 mg) plus a weekly oral placebo or
- A weekly alendronate tablet (70 mg) plus a 6-mo sc placebo injection
After 12 mo, pts completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen

Results

1,583 out of 1,693 (93.5%) answered ≥1 item of the PSQ
More pts preferred and were more satisfied with the 6-mo injection vs weekly tablet
More pts reported no bother with the 6-mo injection (90%) vs weekly tablet (62%)

<< Previous
Addition of infliximab compared with addition of sulfasalazine...

Next >>
Higher sea fish intake is associated with greater bone mass and...